Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (384)
- Scheduling (national classification system) (166)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
23 result(s) found, displaying 1 to 23
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 6 March 2025
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 November 2024
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsThis report provides information about our regulatory performance for the 2023-24 financial year.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
Corporate reportsRead our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsThis Cost Recovery Implementation Statement (CRIS) 2024-2025 provides information on how we implement, and cost recover our regulatory activities.
-
Corporate reportsAn overview of the Medicines Repurposing Program's purpose and history.
-
Corporate reportsThis publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.
-
Corporate reportsRead our 2023 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 March 2023
-
Corporate reportsThe TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 24 November 2022
-
-
Corporate reportsThe Australian Government remains committed to the safety, health and wellbeing of all Australians.
-
Corporate reportsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
Corporate reportsThis Regulation Impact Statement (RIS) is intended to assist the Australian Government in reaching a decision to address the issues relating to the safe use of sports supplements in Australia.
-
Corporate reportsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
Corporate reportsOn Monday, 2 December 2019, a TGA Progress Report to the Senate Mesh Inquiry was tabled in the Senate
-
Corporate reportsFurther comments received on the consultation
-
Corporate reportsThe Australian Government response to the Mesh Senate inquiry has been published.
-
Corporate reportsThis Code supersedes the November 1991 edition of the Australian Code of Good Wholesaling Practice for Therapeutic Goods for Human Use.